Treatment before surgery for early high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 70 with newly diagnosed breast cancer.
- Your cancer must be hormone receptor-positive (ER+) and HER2-negative.
- Your tumor should have a Ki-67 score of 20% or higher and be at a certain stage (T1c-T2 with some lymph node involvement, or T3-T4 any lymph node status).
- You must have at least one measurable tumor according to standard criteria.
- You need to be in good overall health, with an ECOG performance status of 0 or 1.
- You must not have certain autoimmune diseases, active infections, or significant heart or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This trial tests a new combination of two targeted drugs given before surgery to shrink HER2-positive breast cancer. It may help make surgery more successful and reduce the chance of the cancer coming back.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.